

(43) International Publication Date
14 July 2005 (14.07.2005)

PCT

(10) International Publication Number
WO 2005/063298 A1(51) International Patent Classification⁷: A61K 47/12, 47/26, 38/27 (74) Agent: FULLER, Grover, F., Jr.; Pfizer Inc., P.O. Box 1027, MO, St. Louis, MO 63006 (US).

(21) International Application Number: PCT/IB2004/004159

(22) International Filing Date: 13 December 2004 (13.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/531,843 23 December 2003 (23.12.2003) US

(71) Applicant (for all designated States except US): PHARMACIA CORPORATION [US/US]; 700 Chesterfield Parkway West, Chesterfield, MO 63017-1732 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BADKAR, Advait [IN/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017-1732 (US). NEMA, Sandeep [IN/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017-1732 (US). WADHWA, Manpreet [IN/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017-1732 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: STABLE GROWTH HORMONE LIQUID FORMULATION

Freeze-Thaw Stability of Two Commercial hGH Formulations



(57) **Abstract:** The present invention is directed to stable liquid growth hormone formulations that remain stable after physical agitation, and after exposure to one or more freeze-thaw events. Formulations of the present invention can be stored long term at a variety of temperatures, even frozen. In the present invention, a combination of buffer and stabilizing agents, including a non-ionic surfactant (e.g., polysorbate 20), a polymer stabilizer (e.g., polyethylene glycol), and other optional stabilizers combine to provide unexpected stability to aqueous formulations of a growth hormone (e.g., human growth hormone).

WO 2005/063298 A1